Skip to main content
Evidence Snapshot

Mycobacterium tuberculosis

CHEMBL360 ORGANISM Mycobacterium tuberculosis
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-12T22:53:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL360
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mycobacterium tuberculosis as ChEMBL target CHEMBL360. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mycobacterium tuberculosis
ORGANISM · Mycobacterium tuberculosis
As of 2026-09-12
ChEMBL target ID
CHEMBL360
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-12
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-12
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Mycobacterium tuberculosis matters

As of 2026-09-12

Mycobacterium tuberculosis is reviewed as Mycobacterium tuberculosis; the current evidence base includes 21 approved drugs, 105154 compounds, and 9815 assays, with lead potency reaching pChEMBL 9.1.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 21 approved drugs, 105154 compounds, and 9815 assays for this target. The dominant activity type is IC50. CHEMBL374478 is the current potency anchor at pChEMBL 9.1.

Use CHEMBL374478 as the tractability anchor when discussing potency (pChEMBL 9.1).

Activity source · ChEMBL 36 via Core Engine
21 approved pChEMBL 9.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Mycobacterium tuberculosis matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

105154
Total Compounds
9815
Total Assays
21
Approved Drugs
IC50: 3014.0, EC50: 268.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL374478
 9.1 IC50 Approved
No preferred name
CHEMBL43612
 8.9 IC50 —
No preferred name
CHEMBL3612958
 8.6 IC50 —
No preferred name
CHEMBL3612953
 8.6 IC50 —
No preferred name
CHEMBL238592
 8.6 IC50 —

Approved Drugs

Structure Compound First Approval
PRETOMANID
CHEMBL227875
 2019
BEDAQUILINE
CHEMBL376488
 2012
MOXIFLOXACIN
CHEMBL32
 1999
LEVOFLOXACIN
CHEMBL5315124
 1996
CIPROFLOXACIN
CHEMBL8
 1987
AMIKACIN
CHEMBL177
 1981
RIFAMPIN
CHEMBL374478
 1971
ISONIAZID
CHEMBL64
 1952
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-12T22:53:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL360